ASH 2014: Acceleron drugs improve anemia in blood disorders
This article was originally published in Scrip
Executive Summary
Acceleron Pharma's lead product candidates luspatercept and sotatercept reduced or eliminated transfusion dependence for many patients with beta-thalassemia and myelodysplastic syndromes (MDS), but the company's partner Celgene is likely to take only one of the two drugs into later-stage development.
You may also be interested in...
Celgene Notches A Needed Win As Acceleron-Partnered Luspatercept Succeeds In MDS
Celgene delivers positive top-line Phase III results for a key pipeline drug as luspatercept reduces the need for blood transfusions in patients with myelodysplastic syndromes. Partner Acceleron's stock soars ahead of a detailed data presentation later this year.
Finance Watch: Biopharma VC Explosion Extends To Tools, Services
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Need a specific report? 1000+ reports available
Buy Reports